Melodiol Global Health (ASX:ME1DE) EBITDA Margin % : -22.30% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Melodiol Global Health's EBITDA for the six months ended in Dec. 2023 was A$-2.66 Mil. Melodiol Global Health's Revenue for the six months ended in Dec. 2023 was A$11.93 Mil. Therefore, Melodiol Global Health's EBITDA margin for the quarter that ended in Dec. 2023 was -22.30%.

Melodiol Global Health EBITDA Margin % Historical Data

The historical data trend for Melodiol Global Health's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health EBITDA Margin % Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-354.33

-864.30

-451.24

-346.86

-132.96

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial										-310.42	-160.48	-530.90	-313.68	-22.30

Competitive Comparison of Melodiol Global Health's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melodiol Global Health's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's EBITDA Margin % falls into.

Melodiol Global Health EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Melodiol Global Health's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-25.157	/	18.921
	=	-132.96 %

Melodiol Global Health's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.66	/	11.926
	=	-22.30 %

Melodiol Global Health (ASX:ME1DE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Melodiol Global Health EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (ASX:ME1DE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

COPHF:USA

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines